Chemed price target raised to $610 from $580 at Oppenheimer

Oppenheimer analyst Michael Wiederhorn raised the firm’s price target on Chemed to $610 from $580 and keeps an Outperform rating on the shares. Chemed narrowly beat expectations in Q1, as Vitas overcame margin pressure related to excess hiring, the analyst tells investors in a research note. Chemed performed well, and Vitas appears poised to rebound, the firm contends.